Adynxx (ADYX) 10-K 22 Feb 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 22, 2019	Jun. 30, 2018
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 7,482,045
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		5,005,211
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 8,880	$ 2,181
Accounts receivable, net	34	99
Inventory, net	101	93
Prepaid expenses and other current assets	226	41
Current assets of discontinued operations	60	5,062
Total current assets	9,301	7,476
Improvements and equipment, net	200	522
Other assets	178	173
Assets of discontinued operations - noncurrent	0	24,769
Total assets	9,679	32,940
Current Liabilities:
Accounts payable	564	684
Accrued expenses and other current liabilities	385	712
Warrant liability	156	130
Current liabilities of discontinued operations	271	15,443
Total current liabilities	1,376	16,969
Other long-term liabilities	51	59
Long term liabilities of discontinued operations	0	245
Total liabilities	1,427	17,273
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 5,005,211 and 4,986,034 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively	5	5
Additional paid-in capital	166,674	165,672
Accumulated deficit	(158,427)	(150,010)
Total stockholders' equity	8,252	15,667
Total liabilities and stockholders' equity	$ 9,679	$ 32,940

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	5,005,211	4,986,034
Common stock, shares outstanding	5,005,211	4,986,034

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue, net of returns, allowances and discounts	$ 2,216	$ 2,019
Cost of revenues	1,720	1,841
Gross profit	496	178
Operating expenses
Selling, general and administrative	4,778	5,303
Business development costs/(benefit)	1,014	(365)
Total operating expenses	5,792	4,938
Loss from operations	(5,296)	(4,760)
Other (expense) income
Interest income	24	6
Change in fair value of warrant liability	(26)	692
Loss on early extinguishment of debt, net	(1,706)	(182)
Total other (expense) income	(1,708)	516
Loss from continuing operations before tax	(7,004)	(4,244)
Income tax expense	0	0
Loss from continuing operations	(7,004)	(4,244)
Discontinued operations:
Loss from discontinued operations, net of tax of $0 and $0.7 million for the years ended December 31, 2018 and 2017, respectively	(6,901)	(23,159)
Gain on sale of assets, $0.5 million and $0 for the years ended December 31, 2018 and 2017, respectively	5,488	1,696
Loss from discontinued operations, net of tax	(1,413)	(21,463)
Net loss	$ (8,417)	$ (25,707)
Net loss per basic and diluted common share:
Loss from continuing operations	$ (1.42)	$ (0.99)
Discontinued operations:
Loss from discontinued operations, net of tax of $0 and $0.7 million for the years ended December 31, 2018 and 2017, respectively	(1.40)	(5.40)
Gain on sale of assets, $0.5 million and $0 for the years ended December 31, 2018 and 2017, respectively	1.11	0.40
Total from discontinued operations	(0.29)	(5)
Net loss per basic and diluted common share	$ (1.71)	$ (5.99)
Weighted average shares used in computing net loss per basic and diluted common share	4,923,393	4,291,600

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Loss from discontinued operations, net of tax	$ 0	$ 0.7
Gain on sale of assets	$ 0.5	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands		Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2016		$ 32,090	$ 3	$ 156,390	$ (124,303)
Balance (in shares) at Dec. 31, 2016			2,966,904
Issuance common stock for cash, net of issuance costs of $695		5,849	$ 2	5,847
Issuance common stock for cash, net of issuance costs of $695 (in shares)			1,639,825
Stock-based compensation	[1]	2,393	$ 0	2,393
Stock-based compensation (in shares)	[1]		181,936
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition	[2]	675	$ 0	675
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition (in shares)	[2]		101,243
Issuance of common stock in connection with the contingent consideration of the Choice Therapeutics acquisition	[3]	500	$ 0	500
Issuance of common stock in connection with the contingent consideration of the Choice Therapeutics acquisition (in shares)	[3]		131,579
Payment of withholding taxes related to stock-based employee compensation		(133)	$ 0	(133)
Payment of withholding taxes related to stock-based employee compensation (in shares)			(35,453)
Net loss		(25,707)			(25,707)
Balance at Dec. 31, 2017		15,667	$ 5	165,672	(150,010)
Balance (in shares) at Dec. 31, 2017			4,986,034
Stock-based compensation		1,004	$ 0	1,004
Stock-based compensation (in shares)			20,000
Payment of withholding taxes related to stock-based employee compensation		(2)	$ 0	(2)
Payment of withholding taxes related to stock-based employee compensation (in shares)			(823)
Net loss		(8,417)			(8,417)
Balance at Dec. 31, 2018		$ 8,252	$ 5	$ 166,674	$ (158,427)
Balance (in shares) at Dec. 31, 2018			5,005,211
[1]	Includes $374,000 that was part of accrued expenses as of December 31, 2016, which was credited to equity upon the issuance of 60,000 restricted common shares during the year ended December 31, 2017.
[2]	Includes $675,000 that was part of contingent consideration as of December 31, 2016, which was credited to equity upon the issuance of 101,243 common shares during the year ended December 31, 2017.
[3]	Includes $500,000 that was part of contingent consideration as of December 31, 2016, which was credited to equity upon the issuance of 131,579 common shares during the year ended December 31, 2017.

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Parenthetical] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities		$ 374,000
Debt Conversion, Converted Instrument, Shares Issued	60,000
Payments of Stock Issuance Costs	$ 695,000
Celleration, Inc [Member]
Accrued Liabilities		675,000
Debt Conversion, Converted Instrument, Shares Issued	101,243
Choice Therapeutics [Member]
Accrued Liabilities		$ 500,000
Debt Conversion, Converted Instrument, Shares Issued	131,579

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Activities
Net loss	$ (8,417)	$ (25,707)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,881	5,415
Amortization of deferred lease incentive	(21)	(45)
Loss on disposal of property and equipment	89	2
Impairment charges	0	10,300
Deferred income tax expense	0	(743)
Provision for doubtful accounts	13	122
Reserve for note receivable	0	(650)
(Recovery) Provision for excess and slow moving inventory	(8)	68
Stock-based compensation expense	1,004	2,020
Deferred rent	2	2
Accrued interest receivable	0	0
Amortization of debt issuance and discount costs	254	824
Loss on early extinguishment of debt	1,706	182
Warrant modification expense	0	803
Change in fair value of warrant liability	26	(692)
Fair value adjustment of contingent consideration liability	0	35
Gain on sale of assets	(5,488)	(1,696)
Changes in operating assets and liabilities:
Accounts receivable	3,153	(621)
Inventory	(120)	792
Prepaid expenses and other assets	(31)	550
Accounts payable	(1,354)	(1,004)
Accrued expenses and other liabilities	(2,399)	(629)
Net Cash Used in Operating Activities	(9,710)	(10,672)
Investing Activities
Proceeds from sale of assets	29,000	3,411
Purchase of improvements and equipment	0	(179)
Issuance of bridge loan	0	(350)
Release of escrow deposit	300	0
Proceeds from bridge loan	0	1,000
Net Cash Provided by Investing Activities	29,300	3,882
Financing Activities
Contingent purchase price payments	0	(675)
Net proceeds from bridge loan	1,712	0
Repayment of long-term debt	(14,135)	(1,618)
Fees paid on early extinguishment of debt	(466)	(32)
Net proceeds from issuance of common stock	0	5,849
Payment of withholding taxes related to stock-based employee compensation	(2)	(133)
Net Cash (Used In) Provided by Financing Activities	(12,891)	3,391
Net Increase (Decrease) in Cash and Cash Equivalents	6,699	(3,399)
Cash and Cash Equivalents - Beginning of year	2,181	5,580
Cash and Cash Equivalents - End of year	8,880	2,181
Supplemental Disclosure of Cash Flows Information
Interest	362	1,008
Taxes	480	0
Non-cash investing and financing activities:
2016 Accrued bonus awarded in equity	0	374
Common stock issued for contingent purchase price payments	$ 0	$ 1,175

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (“Alliqua” or the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company believes that it is one of the leading manufacturers of high-performance gels in the United States. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has, historically, served as a contract manufacturer, supplying its gels to third parties who incorporate them into their own products. Recent Developments Merger Agreement with TO Pharmaceuticals, LLC. On November 27, 2018, Section 351(a) of the Internal Revenue Code of 1986, as amended. The TOP Merger will occur after the consummation by Alliqua of the following steps: (1) Pursuant to an Asset Contribution and Separation Agreement to be entered into by and between Alliqua and AquaMed (the “Separation Agreement”) prior to consummation of the TOP Merger, Alliqua will transfer certain assets and liabilities utilized primarily in connection with its custom hydrogels contract manufacturing business to AquaMed (the “Separation”), (2) AquaMed will issue a to be determined number of shares of common stock to Alliqua in consideration of the contribution of assets pursuant to the Separation Agreement (the “Distribution Consideration”), (3) Alliqua will distribute to its stockholders all of the issued and outstanding shares of common stock, par value $0.001 per share, of AquaMed by way of a pro rata dividend (the “Distribution”), and (4) Alliqua will consummate the previously announced reverse merger transaction with Adynxx, Inc. (“Adynxx”), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among Alliqua, Embark Merger Sub, Inc. and Adynxx. At the effective time of the TOP Merger, all of the outstanding membership units of TOP will be converted into the right to receive, in the aggregate, merger consideration consisting of shares of AquaMed common stock. Immediately after the effective time of the TOP Merger and consummation of the Private Placement (as defined below), before giving effect to any fees payable in equity to financial advisors or other intermediaries, the current members of TOP and the third-party investors that participate in the Private Placement are expected to hold approximately 90% of the total number of shares of AquaMed common stock outstanding (on a fully diluted basis). The consummation of the TOP Merger is subject to certain customary and other conditions, including (i) the completion of the Separation and the Distribution, (ii) the effectiveness of the registration statement on Form S-1 filed with the SEC with respect to, and the approval for listing on the NASDAQ Capital Market of, the shares of AquaMed common stock to be issued in the Distribution and the TOP Merger, (iii) receipt of binding commitments from third-party investors to consummate a private placement of AquaMed’s common stock in a minimum aggregate amount of $10 million immediately prior to the effective time of the TOP Merger (the “Private Placement”) (iv) the accuracy of the parties’ representations and warranties and the performance of their respective covenants contained in the TOP Merger Agreement, and (v) receipt of an independent third-party valuation of the AquaMed common stock to be issued in the Distribution. The TOP Merger Agreement contains customary and other representations, warranties and covenants, including a covenant for AquaMed to use (i) commercially reasonable efforts to consummate and make effective the Separation and payment of the Distribution Consideration contemplated by the Distribution Agreement in accordance with its terms and (ii) reasonable best efforts to consummate the Private Placement. Merger Agreement with Adynxx On October 11, 2018, the Company, Embark Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Adynxx, Inc., a privately-held Delaware corporation (“Adynxx”), entered into an Agreement and Plan of Merger and Reorganization (the “Adynxx Merger Agreement”), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Adynxx Merger Agreement, Merger Sub will merge with and into Adynxx, with Adynxx becoming a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the “Adynxx Merger”). Subject to the terms and conditions of the Adynxx Merger Agreement, at the effective time of the Adynxx Merger (the “Effective Time”), (a) each outstanding share of Adynxx common stock, on an as-converted basis taking into consideration all outstanding common stock, preferred stock, restricted stock and all other securities convertible or exercisable for Adynxx common stock, will be converted into the right to receive the number of shares of the Company’s common stock (the “Company Common Stock”) equal to the exchange ratio described below; (b) each outstanding Adynxx stock option that has not previously been exercised prior to the Effective Time will be assumed by the Company; and (c) each outstanding warrant to acquire Adynxx capital stock that has not previously been exercised prior to the Effective Time will be assumed by the Company. Under the exchange ratio formula in the Adynxx Merger Agreement, as of immediately after the Adynxx Merger, but excluding the effect of certain financings (as further described in the Adynxx Merger Agreement), the former Adynxx securityholders are expected to own approximately 86% of the aggregate number of shares of the Company Common Stock issued and outstanding following the consummation of the Adynxx Merger (the “Post-Closing Shares”), and the stockholders of the Company as of immediately prior to the Adynxx Merger are expected to own approximately 14% of the aggregate number of Post-Closing Shares. This exchange ratio will be fixed immediately prior to the Effective Time to reflect the Company’s and Adynxx’s equity capitalization as of immediately prior to such time. In addition, to the extent Adynxx consummates a Permitted Financing, as specifically defined in the Adynxx Merger Agreement, in excess of $10.0 million dollars prior to the Effective Time, the exchange ratio may be further adjusted in a manner that would reduce the percentage of the aggregate number of Post-Closing Shares held by stockholders of the Company as of immediately prior to the Adynxx Merger. Immediately following the Adynxx Merger, the name of the Company will be changed from “Alliqua BioMedical, Inc.” to “Adynxx, Inc.” At the Effective Time, the Adynxx Merger Agreement contemplates that the Board of Directors of the Company will consist of such directors selected by Adynxx, with the Company having the right to designate one member. The executive officers of the Company immediately after the Effective Time will be designated by Adynxx; the merger will be a change of control and accounted for as a reverse business combination whereby Adynxx will be deemed the accounting acquiror. The Adynxx Merger Agreement contains customary representations, warranties and covenants made by the Company and Adynxx, including covenants relating to obtaining the requisite approvals of the stockholders of the Company and Adynxx, indemnification of directors and officers, and the Company’s and Adynxx’s conduct of their respective businesses between the date of signing the Adynxx Merger Agreement and the closing of the Adynxx Merger. Consummation of the Adynxx Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Adynxx. The Adynxx Merger Agreement contains certain termination rights for both the Company and Adynxx, and further provides that, upon termination of the Adynxx Merger Agreement under specified circumstances, the Company or Adynxx, as applicable, may be required to pay the other party a termination fee of $0.249 million. The Adynxx Merger Agreement contemplates that the Company will also seek approval from its stockholders to effect a reverse stock split, if applicable, with the split ratio to be mutually agreed to by the Company and Adynxx within the range approved by the Company’s stockholders immediately prior to the Effective Time. In addition, the Adynxx Merger Agreement requires the Company to use commercially reasonable efforts to consummate a spin-off of its hydrogel contract manufacturing business prior to the closing of the Adynxx Merger. The Company’s operations contemplated under the Adynxx Merger Agreement are classified as Held for Use. Asset Sale Transaction with Celularity On May 7, 2018, the Company completed the Asset Sale Transaction (the “AST”) with Celularity, Inc. (“Celularity”), pursuant to which the Company sold substantially all of its assets to Celularity, including certain assets comprising its MIST, Biovance and Interfyl Product Lines (the “Purchased Assets”). As consideration for the Purchased Assets, Celularity paid $29.0 million to the Company in cash. No debt or significant liabilities were assumed by Celularity in the AST. Under the terms of the Asset Purchase Agreement (the “APA”), the Company retained certain specified assets, including, among other things, cash, accounts receivable, and its hydrogel contract manufacturing business, including its SilverSeal and Hydress product lines. Approximately $14.8 million of the consideration received from Celularity was used to pay down in full all outstanding debt and related costs owed to Perceptive Credit Holdings LP (“Perceptive”). The transactions contemplated by the APA were approved by the affirmative vote of a majority of the voting power of issued and outstanding shares of the Company’s common stock on April 27, 2018. The Company’s operations sold under the APA have been reclassified to discontinued operations in the second quarter of 2018, when the shareholders of the Company approved the sale. The AST was completed on May 7, 2018. Principles of Consolidation The accompanying consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported. Reverse Stock Split The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates in the Financial Statements The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2018 and 2017 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings. Trade Accounts Receivable Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowances for doubtful accounts is recorded based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was nominal for December 31, 2018 and 2017. Inventory Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf life expiration dates for products. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value. Improvements and Equipment Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the lesser of the lease term or the estimated useful life. Repairs and maintenance costs are expensed as incurred. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. Goodwill and Other Indefinite-Lived Intangible Assets The Company records goodwill and other indefinite-lived assets in connection with business combinations. Goodwill, which represents the excess of acquisition cost over the fair value of the net tangible and intangible assets of acquired companies, is not amortized. Indefinite-lived assets are stated at fair value as of the date acquired in a business combination. The Company assesses the recoverability of goodwill and certain indefinite-lived intangible assets annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level. Under Financial Accounting Standards Board (“FASB”) guidance for goodwill and intangible assets, a reporting unit is defined as an operating segment or one level below the operating segment, called a component. However, two or more components of an operating segment will be aggregated and deemed a single reporting unit if the components have similar economic characteristics. The Company operates as one reporting unit. Authoritative accounting guidance allows the Company to first assess qualitative factors to determine whether it is necessary to perform the more detailed two-step quantitative goodwill impairment test. The Company performs the quantitative test if its qualitative assessment determined it is more likely than not that a reporting unit’s fair value is less than its carrying amount. The Company may elect to bypass the qualitative assessment and proceed directly to the quantitative test for any reporting unit or asset. The quantitative goodwill impairment test, if necessary, is a two-step process. The first step is to identify the existence of a potential impairment by comparing the fair value of a reporting unit (the estimated fair value of a reporting unit is usually calculated using a discounted cash flow model) with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, the reporting unit’s goodwill is considered not to be impaired and performance of the second step of the quantitative goodwill impairment test is unnecessary. However, if the carrying amount of a reporting unit exceeds its fair value, the second step of the quantitative goodwill impairment test is performed to measure the amount of impairment loss to be recorded, if any. The second step of the quantitative goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined using the same approach as employed when determining the amount of goodwill that would be recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of its assets and liabilities as if the reporting unit had been acquired in a business combination and the fair value was the purchase price paid to acquire the reporting unit. The Company proceeded directly to the quantitative analysis considering the consideration to be received and the assets to be sold under the APA. As a result of this test, the Company’s goodwill was determined to be impaired and an impairment charge of $10.3 million was recorded for the year ended December 31, 2017. As of May 7, 2018, as a result of completing the Celularity AST, the Goodwill and Intangible Assets have been disposed of. At December 31, 2017 the remaining recorded goodwill was $1,659,000, included in assets of discontinued operations – noncurrent on the consolidated balance sheet. The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017, are as follows (in thousands): Goodwill Balance as of $ 11,959 Impairment loss (10,300 ) Balance as of December 31, 2017 1,659 Disposal of Intangible Assets, Asset Sale (1,659 ) Balance as of December 31, 2018 $ 0 Long-Lived Assets Long-lived assets, such as property and equipment, and intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company’s long-lived intangible assets primarily consist of developed technology, customer lists/relationships, non-compete agreements, trade names and trademarks and are amortized ratably over a range of one to ten years which approximates customer attrition rate and technology obsolescence. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment is based on generally accepted valuation methodologies, as deemed appropriate. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, the present value of future cash flows, net of estimated operating costs, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. Due to the APA, the long-lived asset group related to the Purchased Assets were sold and otherwise disposed of significantly before the end of its previously estimated useful life. The Company, therefore, tested its long-lived assets for recoverability as of December 31, 2017. These long-lived assets consist of property, plant and equipment and intangible assets subject to amortization. The consideration under the APA for the sale of the long-lived assets approximate the net book value of these assets at December 31, 2017, therefore, no impairment charge was recorded for long-lived assets during the year ended December 31, 2017. There were no long-lived assets as of December 31, 2018, due to the Celularity AST. Fair Value of Financial Instruments The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Cost of Goods Sold and Selling, General and Administrative Expenses Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature. Shipping and Handling Amounts billed to customers for shipping and handling are included in revenues. The related shipping and freight charges incurred by the Company are included in cost of goods sold and were not material for either the years ended December 31, 2018 or 2017. Business Development The Company accounts for costs due to professional fees, including accounting, legal and consulting fees related to business developments; in the past these were in other expenses and professional fees as part of general and administrative expenses, however because they are not of a normal course of business, these have been reclassified and presented separately within the Company’s statement of operations. During the year ended December 31, 2018, we incurred business development costs of $1.0 million and during the year ended December 31, 2017, we received a benefit of $0.366 million in development due, in part, to the repayment of a portion of the bridge loan to Soluble Systems, LLC that had been previously written off at the time the proposed transaction was terminated. Income Taxes The Company accounts for income taxes pursuant to the asset and liability method which requires us to recognize current tax liabilities or receivables for the amount of taxes the Company estimate are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2018 and 2017. As of December 31, 2018 and December 31, 2017, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. Common Stock Purchase Warrants The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required. The Company’s free-standing derivatives consist of warrants to purchase common stock that were issued pursuant to a Securities Purchase Agreement on November 8, 2012 (which expired in November 2017) and pursuant to a Credit Agreement on May 29, 2015. The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions. Accordingly, the outstanding portions of these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2018 and 2017. The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment. Recent Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, "Leases (Topic 842)." ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements" in July 2018, and ASU No. 2018-20 "Leases (Topic 842) - Narrow Scope Improvements for Lessors" in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company expects to adopt ASU 2016-02 effective January 1, 2019, upon adoption of Topic 842, the Company expects recognition of additional assets and corresponding liabilities pertaining to its operating leases on its consolidated balance sheets. The Company does not expect the adoption of the new standard to have a significant impact on its consolidated statements of operations and cash flows. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement”. The amendments in this update is to improve the effectiveness of disclosures in the notes to the financial statements by facilitating clear communication of the information required by GAAP that is most important to users of each entity’s financial statements. The amendments in this Update apply to all entities that are required, under existing GAAP, to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”. The amendments in this update is to maintain or improve the usefulness of the information provided to the users of financial statements while reducing cost and complexity in financial reporting. The areas for simplification in this Update involve several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. On December 22, 2017 the U.S. government enacted significant changes to federal tax law following the passage of the Tax Cuts and Jobs Act (“the Act”). Following the enactment of the Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”). The Company follows the guidance in SAB 118, which provides additional clarification regarding the application of US GAAP in situations where the Company does not have the necessary information available, prepared, or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Act for the reporting period in which the Act was enacted. SAB 118 provides for a measurement period beginning in the reporting period that includes the Act’s enactment date and ending when the Company has obtained, prepared, and analyzed the information needed in order to complete the accounting requirements but in no circumstances should the measurement period extend beyond one year from the enactment date. During the quarter ended December 31, 2018, the Company completed the accounting for the income tax effects of the Act, which resulted in an immaterial change in the net deferred tax asset, before valuation allowance, as of the enactment date. These impacts are disclosed in “Note 15 – Income Taxes” in the Notes accompanying the audited Consolidated Financial Statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The Company adopted ASU 2017-09 during the year ended December 31, 2018, In January 2017, the FASB issued ASU 2017-01 “Business Combinations (Topic 805): Clarifying the Definition of a Business”, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company adopted ASU 2017-01 during the year ended December 31, 2018, and the adoption did not have a material impact on its financial statements. In December 2016, the FASB issued ASU 2016-18 “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force,” which clarifies the presentation requirements of restricted cash within the statement of cash flows. The changes in restricted cash and restricted cash equivalents during the period should be included in the beginning and ending cash and cash equivalents balance reconciliation on the statement of cash flows. When cash, cash equivalents, restricted cash or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity shall calculate a total cash amount in a narrative or tabular format that agrees to the amount shown on the statement of cash flows. Details on the nature and amounts of restricted cash should also be disclosed. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company adopted ASU 2016-18 during the year ended December 31, 2018 In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduce the current diversity in practice. ASU No. 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017, with early application permitted. This guidance is applicable to the Company’s fiscal year beginning January 1, 2018. The Company has adopted ASU 2016-15 during the year ended December 31, 2018, In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company has adopted ASU 2016-09 during the year ended December 31, 2018, In May 2014 the FASB issued Accounting Standards No. 2014-09, Revenue from Contracts with Customers (Topic 606), in May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606)—Narrow Scope Improvements and Practical Expedients These standards and their effect on the Company’s consolidated financial statements and related disclosures are discussed below under Note 4, Revenue Recognition.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	3. Liquidity The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses since its inception. For the year ended December 31, 2018, the Company incurred a net loss of $8.4 million, utilized $9.8 million in cash from operations and had an accumulated deficit of $158.4 million. Prior to closing of the APA on May 7, 2018, these factors raised substantial doubt as to the Company’s ability to continue as a going concern. However, upon closing the APA, the Company received gross proceeds of $29.0 million and part of the proceeds, $14.8 million, were utilized to satisfy, in full, its obligations under the Credit Agreement and Guaranty (the “CAG”) with Perceptive. As of December 31, 2018, the Company had a cash balance of approximately $8.9 million. Given the Company’s current cash position and reduced cash burn, the Company believes substantial doubt has been mitigated and it has sufficient resources to support its planned operations for a year from the date these financial statements are issued.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	4. Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing accounting principles generally accepted in the United States of America (“U.S. GAAP”) including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s consolidated financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required. The Company recognizes revenue predominately from one type of revenue, contract manufacturing and recognizes an immaterial amount from the sale of products. Revenue from both contract manufacturing and products is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. To achieve this core principle, the Company applies the following five steps: Step 1 – Identify the Contract with the Customer – A contract exists when (a) the parties to the contract have approved the contract and are committed to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract has commercial substance and it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Step 2 – Identify Performance Obligations in the Contract – Upon execution of a contract, the Company identifies as performance obligations each promise to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation. Step 3 – Determine the Transaction Price – The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer. Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine the amount of variable consideration that should be included in the transaction price based on expected value method. Variable consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract would not occur. Step 4 – Allocate the Transaction Price – After the transaction price has been determined, the next step is to allocate the transaction price to each performance obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations based on the relative standalone selling price (SSP) at contract inception. Step 5 – Satisfaction of the Performance Obligations (and Recognize Revenue) – When the customer obtains control of the asset (or the services are rendered), the Company recognizes revenue. At contract inception, the Company determines if each performance obligation is satisfied at a point in time or over time. Revenue from both product sales and contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. Disaggregation of Revenue The Company recognizes revenue predominately from contract manufacturing and recognizes an immaterial amount from products. Revenue from both products and contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. As of December 31, 2018, or December 31, 2017, the Company did not have any contract assets or contract liabilities from contracts with customers. During the year ended December 31, 2018 and 2017, there was no revenue recognized from performance obligations satisfied (or partially satisfied) in previous periods. As of December 31, 2018, there were no remaining performance obligations that the Company had not satisfied.

Net Loss Per Common Share

Net Loss Per Common Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	5. Net Loss Per Common Share Basic loss per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted loss per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: As of December 31, 2018 2017 Stock options 375,591 809,586 Warrants 276,478 478,330 Non-vested restricted stock 20,000 189,674 Total 672,069 1,477,590

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	6. Discontinued Operations Asset Sales In addition to the aforementioned AST with Celularity, in order to add capital and to focus on future investments on commercializing its own regenerative technologies on August 31, 2017, the Company entered into an Asset Purchase Agreement (“the Argentum Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Argentum Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $3.6 million for the TheraBond product line and certain other agreements between the parties and (ii) up to $112,000 for the unsold TheraBond inventory upon the Company’s completion of its obligations to deliver all remaining and qualifying unsold TheraBond inventory, as specified in the Argentum Purchase Agreement. Of the $3.6 million of consideration, $300,000 was deposited in an indemnity escrow account under standard terms and conditions. This amount is classified under current assets of discontinued operations on the Company’s balance sheet as of December 31, 2017. As of December 31, 2018, the indemnity escrow has been repaid. Summarized operating results of discontinued operations for the years ended December 31, 2018 and 2017 are presented in the following table (in thousands): Year Ended December 31, 2018 2017 Revenue, net of returns, allowances and discounts $ 6,681 $ 18,790 Cost of revenues 1,791 5,319 Gross profit 4,890 13,471 Selling, general and administrative 11,179 34,488 Other income - (200 ) Interest expense 612 2,282 Warrant modification expense - 803 Deferred income tax benefit - (743 ) Loss from discontinued operations, net of tax (6,901 ) (23,159 ) Non-cash amortization expense of $1.4 million and $4.4 million is included in selling, general and administrative expense for the years ended December 31, 2018 and 2017, respectively. During the year ended December 31, 2018, the Company recorded a net gain of approximately $5.5 million (net of state income tax of $0.546 million) on the sale of the assets related to the purchase agreement with Celularity, as shown in the following table (in thousands): Proceeds from sale Total Consideration 29,000 Less: Net book value of assets sold to Celularity Inventory, net (1,578 ) Intangibles, net (20,557 ) Goodwill (1,659 ) Fixed Assets, net (904 ) Other current assets 15 Total net book value of assets (24,683 ) Add: Net book value of liabilities extinguished due to sale Milestone payment 1,000 Other liabilities 717 Total net book value of liabilities 1,717 Less: State tax expense (546 ) Net gain on sale of assets $ 5,488 Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands): December 31, December 31, 2018 2017 Accounts receivable, net $ 60 $ 3,161 Inventory, net - 1,458 Prepaid expenses and other current assets - 443 Total current assets 60 5,062 Fixed assets, net - 1,041 Intangible assets, net - 22,069 Goodwill, net - 1,659 Total assets of discontinued operations 60 29,831 Accounts payable 271 957 Accrued expenses and other current liabilities - 3,557 Senior secured term loan, net - 10,929 Total current liabilities $ 271 $ 15,443 Other long-term liabilities - 245 Total liabilities of discontinued operations $ 271 $ 15,688 During the year ended December 31, 2017, the Company recorded a gain of approximately $1.7 million (net of tax of $ 0 Proceeds from sale Consideration for inventory $ 112 Consideration for intangible assets 3,600 Total Consideration 3,712 Less: Net book value of assets sold to Argentum Inventory, net (307 ) Intangibles, net (1,709 ) Total net book value of assets (2,016 ) Gain on sale of assets $ 1,696 On August 31, 2017, the Company entered into a ninety-day transition services agreement with Argentum (“Transition Agreement”). Under the Transition Agreement, the Company is required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the TheraBond product line to Argentum, as specified in the Transition Agreement. As compensation, Argentum paid the Company $200,000 for the services completed during the period from the closing of the purchase for three months ended November 30, 2017. This compensation was recognized over the service period and is included in discontinued operations for the year ended December 31, 2017. On September 12, 2018, the obligation was paid in full and as of December 31, 2018, no obligation is owed by Argentum.

Termination of Merger Agreement

Termination of Merger Agreement	12 Months Ended
	Dec. 31, 2018
Disclosure Text Block Supplement [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	7. Termination of Merger Agreement On October 5, 2016, the Company entered into a merger agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. On February 27, 2017, the Company terminated this agreement. In connection with the merger agreement to acquire the business of Soluble, the Company provided Soluble with bridge loans in the form of subordinated promissory notes totaling approximately $1.4 million. The Company advanced Soluble $1.0 million during the year ended December 31, 2016 and $0.4 million on January 30, 2017. Pursuant to the terms of the merger agreement, the amount was to be repaid in full upon termination of the agreement. As of December 31, 2016, the Company had provided for a full reserve for the amount that had been advanced to Soluble as of that date. On October 27, 2017, the Company received $1 million under an agreement with Soluble in connection with amounts advanced to Soluble by the Company. With the receipt of this $1 million, the Company acknowledged that all amounts due to the Company from Soluble are paid in full. During the year ended December 31, 2017, the Company recorded a reduction in acquisition-related expenses of $365,000 which consisted of the recovery of bad debt expense of $650,000, offset by approximately $285,000 of other acquisition-related expenses.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	8. Inventory Inventory consists of the following (dollars in thousands): December 31, December 31, 2018 2017 Raw materials $ 101 $ 98 Less: Inventory reserve for excess and slow moving inventory - (5 ) Total $ 101 $ 93

Improvements and Equipment, net

Improvements and Equipment, net	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	9. Improvements and Equipment, net Improvements and equipment consist of the following (in thousands): December 31, Useful Life 2018 2017 (Years) Machinery and equipment 3-10 $ 2,893 $ 2,893 Office furniture and equipment 3-10 49 56 Leasehold improvements (A) 228 228 3,170 3,177 Less: Accumulated depreciation and amortization (2,970 ) (2,655 ) Improvements and equipment, net $ 200 $ 522 (A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life. Depreciation and amortization expense was $0.315 million and $0.315 million for the years ended December 31, 2018 and 2017, respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	10. Accrued Expenses Accrued expenses and other current liabilities consist of the following (in thousands): December 31, December 31, 2018 2017 Salaries, benefits and incentive compensation $ 108 $ 509 Professional fees 230 176 Other 47 27 Total accrued expenses and other current liabilities $ 385 $ 712

Operating Leases

Operating Leases	12 Months Ended
	Dec. 31, 2018
Leases, Operating [Abstract]
Leases of Lessee Disclosure [Text Block]	11. Operating Leases The Company leases one commercial manufacturing facility through an operating lease agreement. The Company has an obligation for its commercial manufacturing facility located in Langhorne, Pennsylvania, through 2026. The Company leases one corporate office through an operating lease agreement, located in Yardley, Pennsylvania which, , this property has been subleased to The Pinnacle Health Group, Inc. through April 20, 2023 and the Company receives monthly lease payments. Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases at December 31, 2018 are as follows (in thousands): Gross Lease Payments Sublet Lease Payments Net Lease Payments 2019 $ 430 $ 223 $ 207 2020 434 227 207 2021 439 232 207 2022 443 236 207 2023 287 80 207 Thereafter 434 - 434 Total $ 2,467 $ 998 $ 1,469 Total rent expense for the Langhorne facility was $0.207 million and $0.207 million for the years ended December 31, 2018 and 2017, respectively. . Total rent payments for the Yardley facility was $0.230 million and $0.218 million for the years ended December 31, 2018 and 2017, respectively. The Company leased an additional corporate office through May 7, 2018, located in Eden Prairie, Minnesota, through the completion of the AST to Celularity, this lease has been fully reassigned to Celularity and is no longer an obligation to the Company.

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Debt Instruments [Abstract]
Long-term Debt [Text Block]	12. Debt Senior Secured Term Loan Facility On May 29, 2015, the Company entered into a with Perceptive. The CAG provided a senior secured term loan in a single borrowing to the Company in the principal amount of $15.5 million. In connection with the entry into the Credit Agreement, a five-year warrant (the “Warrant”) to purchase 75,000 shares of common stock, par value of $0.001 per share at an exercise price of $55.138 per share (the “Exercise Price”) was issued to Perceptive. The Company granted Perceptive customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon exercise of the Warrant. The warrant contains a weighted average anti-dilution feature whereby the Exercise Price is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the current Exercise Price. As a result, the warrant was determined to be a derivative liability. The warrant had an issuance date fair value of approximately $2.7 million which was recorded as a debt discount. During the years ended December 31, 2018 and 2017, the Company recorded amortization of debt discount of $0.178 million and $0.577 million, respectively, which is included in discontinued operations for the periods presented. See Note 18 – Fair Value Measurement for additional details. On March 13, 2018, the Company AquaMed Technologies, Inc., a wholly owned subsidiary of the Company and Perceptive entered into an Amendment Agreement, pursuant to which the parties agreed to certain amendments and modifications to the terms of the CAG. The Amendment Agreement provided for, an additional bridge term loan to the Company in the aggregate principal amount of $2.0 million pursuant to a Bridge Loan Note (“BLN”). Under the Amendment Agreement, the Company agreed to pay an upfront fee of $0.25 million and all fees, costs and expenses payable pursuant to the CAG (including reasonable attorney’s fees of Perceptive). The BLN bore interest at a rate per annum equal to the sum of (i) the greater of (x) LIBOR and (y) 1%, plus (ii) an applicable margin of 9.75%. The BLN matured on the earlier of (i) May 7, 2018 and (ii) the closing date in connection with the APA. On May 7, 2018, the Company paid approximately $14.8 million, which included $ 0.2 in full satisfaction of all debt obligations due Perceptive. Consent and Forbearance Agreement On August 31, 2017, in connection with the Argentum Purchase Agreement, the Company and Perceptive entered into a Consent, Forbearance and Amendment Agreement (the “Consent and Forbearance Agreement”), pursuant to which the Company agreed to pay $1,650,000 of the proceeds from the Argentum Purchase Agreement to Perceptive, of which approximately $1,618,000 was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $32,000 was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the year ended December 31, 2017, the Company recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $32,000 prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $53,000 of unamortized debt issuance costs.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and Contingencies Agreements for Human Placental Based Products with Celularity, Inc. In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) and Supply Agreement (the “Biovance Supply Agreement”) with Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). The Company is required to pay Celularity annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. During the years ended December 31, 2018 and 2017, the Company incurred royalties of approximately $381,000 and $818,000, respectively, in connection with this agreement. Approximately $0 and $227,000 is included in discontinued operations as of December 31, 2018 and December 31, 2017, respectively, in connection with this agreement. In April 2016, the Company entered into a Supply Agreement with HLI (now Celularity), pursuant to which Celularity supplies the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix. On May 7, 2018, the License Agreement and the Supply Agreements were transferred to Celularity in connection with the completion of the AST. License Agreement with Noble Fiber Technologies, LLC On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75% of net sales of licensed products. There are no minimum royalties subsequent to 2016. Total royalties, for the years ended December 31, 2018 and 2017 were nominal, in connection with this agreement. There was no outstanding payable as of December 31, 2018 and 2017, respectively, in connection with this agreement. Contingent Consideration Celleration, Inc. On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds. The Company agreed to pay contingent consideration of 3.5 times revenue from acquired MIST Therapy products in excess of certain revenue targets for the years ending December 31, 2015 and 2016, payable in equal amounts of cash and the Company’s common stock. This contingent consideration was payable in two installments in March 2016 and March 2017. The second installment consisted of $675,000 of cash and approximately 101,000 shares of the Company’s common stock valued at approximately $675,000 and was paid in March 2017. This payment was based on 3.5 times of the excess of 2016 MIST Therapy revenue of approximately $10.5 million over 2015 MIST Therapy revenue of approximately $10.2 million. There are no further contingent payments due in connection with the Celleration acquisition. Choice Therapeutics, Inc. On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D® Antimicrobial Barrier Systems. The Company agreed to pay contingent consideration based upon the Company achieving specific performance metrics over the three twelve-month periods, ended April 30, 2017. The Company issued approximately 132,000 Litigation, Claims and Assessments The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The company is not party to any material litigation as of December 31, 2018. The class action complaint filed on February 22, 2018 was settled in April 2018 for an immaterial amount, $0.125 million.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	14. Stockholders’ Equity Preferred Stock The Company has authorized 1,000,000 shares of preferred stock, $0.001 par value per share, which may be divided into series and with preferences, limitations and relative rights determined by the Board of Directors. Common Stock The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 6, 2017. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split. 2011 Plan The Company maintains the 2011 Long-Term Incentive Plan (the “2011 Plan”) that provides for the granting of stock options, restricted stock units (“RSUs”), restricted stock and other awards to employees, directors and others. A total of 182,857 shares of common stock have been authorized for issuance under the 2011 Plan, of which, as of December 31, 2018, 54,131 shares were available for future issuances. 2014 Plan The Company maintains the 2014 Long-Term Incentive Plan (the “2014 Plan”) that provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. On February 26, 2015 and May 6, 2015, the Company’s Board of Directors and the Company’s shareholders, respectively, approved an amendment to the 2014 Plan to increase the total number of shares of common stock authorized for issuance under the 2014 Plan by an additional 350,000 shares. On April 26, 2017 and June 23, 2017, the Company’s Board of Directors and the Company’s shareholders, respectively, approved an amendment to the 2014 Plan to increase the total number of shares of common stock authorized for issuance under the 2014 Plan by an additional 400,000 shares. A total of 950,000 434,616 Private Placement On February 27, 2017, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the “Private Placement”) an aggregate of 554,000 shares of the Company’s common stock at a purchase price of $5.00 per share. The Company closed the Private Placement on the same day as it entered into the Securities Purchase Agreement and received aggregate gross proceeds of approximately $2.8 million. In connection with the Private Placement, the Company paid an aggregate of $196,000 of financial advisory fees and $40,000 of administrative fees, which were recorded as a reduction of additional paid-in capital. The Securities Purchase Agreement contains a “most-favored nation” provision that provides that if the Company, during 120 days from February 27, 2017, issues or sells any common stock or common stock equivalents reasonably believed to be more favorable in terms or conditions than those in the Private Placement, then the Company must amend the terms of the Securities Purchase Agreement to give the private investors the benefit of such favorable terms or conditions. In connection with the common stock sold in the Public Offering (as defined below) and in accordance with this provision, on April 11, 2017, the Company issued an aggregate of 38,072 shares of its common stock to these investors. On June 23, 2017, the Company held its 2017 annual meeting of stockholders during which the stockholders approved the issuance of the remaining 100,428 additional shares of common stock to be issued to the investors, and, following the meeting, on June 23, 2017, the Company issued the remaining shares. Underwritten Public Offering On April 3, 2017, the Company closed an underwritten public offering (the “Public Offering”) of 947,325 shares of its common stock at a price to the public of $4.00 per share. The Company received aggregate gross proceeds of approximately $3.8 million. In connection with the Public Offering, the Company paid an aggregate of $365,000 of financial advisory fees and $92,000 of administrative fees, which were recorded as a reduction of additional paid-in capital. The shares of common stock were issued pursuant to the Company’s shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission and declared effective on September 25, 2014. On April 3, 2017, the Company issued warrants to purchase an aggregate of 23,686 of the Company’s common stock to the underwriter of this offering. These warrants are immediately exercisable, have an exercise price of $4.40, and expire on March 29, 2022. The warrants had an aggregate issuance date fair value of $78,000 which was recorded as both a debit and credit to additional paid in capital. Pursuant to an anti-dilution provision provided in the warrants dated November 8, 2012 to purchase common stock at an initial exercise price of $21.90, the exercise price of these warrants was adjusted to the public offering price of $4.00. As of April 3, 2017, November 2012 warrants to purchase 36,231 shares of the Company’s common stock were outstanding. These warrants expired in November 2017. Stock-Based Compensation On May 7, 2018, in connection with the closing of the sale under the APA of substantially all of the Company’s assets to Cellularity, which triggered certain change in control provisions of the Company’s equity plans, all unvested and outstanding options and restricted stock awards under the 2011 Plan and 2014 Plan became vested and exercisable. For the year ended December 31, 2018, the Company recognized $1.0 million of stock-based compensation expense, of which, $0.03 million is included in cost of revenues and $0.97 million is included in selling, general and administrative expenses in the consolidated statements of operations. For the year ended December 31, 2017, the Company recognized $2.0 million of stock-based compensation expense, of which, $0.045 is included in cost of revenues and $2.0 million is included in selling, general and administrative expenses in the consolidated statements of operation. As of December 31, 2018, there was no unrecognized stock-based compensation expense remaining. Restricted Stock During the year ended December 31, 2017, the Company granted an aggregate of 181,936 shares of restricted stock to employees with an aggregate grant date value of $621,000, which will be recognized proportionate to the vesting period. The shares vest as follows: (i) 66,936 shares vest on September 21, 2017, (ii) 5,000 shares vest on December 31, 2017, (iii) 50,000 shares vest on June 23, 2018, and (iv) 60,000 shares vest pursuant to the satisfaction of certain performance conditions. During the year ended December 31, 2018, the Company granted an aggregate of 20,000 shares of restricted stock to consultants with an aggregate grant date value of $39,200, which will be recognized proportionate to the vesting period. The shares vest pursuant to the satisfaction of certain performance conditions. A summary of restricted stock award activity during the years ended December 31, 2018 and 2017 is presented below (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Total Grant Date Fair Value Non-vested, December 31, 2016 147 $ 26.26 $ 3,862 Granted 182 3.41 621 Vested (137 ) 17.35 (2,373 ) Forfeited (2 ) 3.87 (10 ) Non-vested, December 31, 2017 190 $ 11.07 $ 2,100 Granted 20 1.96 39 Vested (185 ) 11.07 (2,045 ) Forfeited (5 ) 11.07 (55 ) Non-vested, December 31, 2018 20 $ 1.96 $ 39 Warrants There were no compensatory warrants issued during the years ended December 31, 2018 and 2017. A summary of the warrant activity during the years ended December 31, 2018 and 2017 is presented below (in thousands, except years and per warrant data): Number of Warrants Weighted Average Exercise Price per Warrant Weighted Average Remaining Life in Years Intrinsic Value Outstanding, December 31, 2016 337 $ 56.90 Issued 159 4.66 Adjustment for price reset 29 Exercised - - Forfeited (47 ) 9.35 Outstanding, December 31, 2017 478 $ 32.79 $ - Issued - - Exercised - - Cancelled (202 ) 50.03 Outstanding, December 31, 2018 276 $ 20.20 2.7 $ - Exercisable, December 31, 2018 276 $ 20.20 2.7 $ - The following table presents information related to warrants at December 31, 2018 (in thousands, except years and per warrant data): Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Number of Warrants Weighted Average Remaining Life in Years Exercisable Number of Warrants $4.40 - $39.99 233 3.1 233 $40.00 - $105.00 43 0.3 43 276 2.4 276 Stock Options During 2017, the Company granted ten-year options to purchase an aggregate of 258,105 shares of common stock at exercise prices ranging from $2.09 to $5.70 per share with an aggregate grant date value of $642,000 to non-executive employees and directors pursuant to the 2014 Plan. The options vest as follows: (i) 45,045 shares vest one-twelfth monthly over one year, and (ii) 213,060 shares vest in one-fourth increments every six months over a period of two years. The grant date value is being amortized over the vesting term. In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: Year Ended December 31, 2018 2017 Risk free interest rate N/A 1.81%-2.43 % Expected term (years) N/A 5.04-6.50 Expected volatility N/A 81.94% - 87.00 % Expected dividends N/A 0.00 % The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the “simplified method” to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to options at annual rates ranging from 0% to 5% for options outstanding at December 31, 2018 and 2017. There were no options granted during the year ended December 31, 2018. The weighted average estimated grant date fair value of the options granted during the year ended December 31, 2017 was $2.49 per share. A summary of the stock option activity during the years ended December 31, 2018 and 2017 is presented below (in thousands, except years and per option data): Number of Options Weighted Average Exercise Price per Option Weighted Average Remaining Life in Years Intrinsic Value Outstanding, December 31, 2016 720 $ 52.90 Granted 258 3.53 Exercised - - Forfeited (168 ) 40.60 Outstanding, December 31, 2017 810 $ 39.67 Granted - - Exercised - - Forfeited (434 ) 31.42 Outstanding, December 31, 2018 376 $ 49.29 4.3 $ - Exerciseable, December 31, 2018 376 $ 49.29 4.3 $ - As a result, a summary of the Company’s outstanding and exercisable options as of December 31, 2018 was as follows (in thousands, except years and per option data): Options Outstanding Options Exercisable Range of Exercise Price Weighted Average Exercise Price Outstanding Number of Options Weighted Average Exercise Price Weighted Average Remaining Life in Years Exercisable Number of Options $2.00 - $4.00 $ 3.64 52 3.64 8.5 52 $4.10 - $9.90 8.72 23 8.72 7.4 23 $10.00 - $19.90 10.50 8 10.50 7.2 8 $20.00 - $39.90 33.47 40 33.47 4.4 40 $40.00 - $49.90 44.54 33 44.54 3.3 33 $50.00 - $59.90 53.87 26 53.87 1.2 26 $60.00 - $69.90 65.91 152 65.91 3.6 152 $70.00 - $79.90 79.40 1 79.40 5.3 1 $80.00 - $89.90 87.50 18 87.50 2.2 18 $90.00 - $99.90 90.00 18 90.00 2.1 18 $100.00 - $266.90 109.40 5 109.40 1.4 5 49.29 376 49.29 4.3 376

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	15. Income Taxes The Company files corporate income tax returns in U.S. federal, state and local jurisdictions, including Pennsylvania, and has tax returns subject to examination by tax authorities generally beginning in the year ended December 31, 2015 and through December 31, 2018. However, to the extent we utilize our net operating loss (“NOL”) carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is utilized. The income tax (benefit) provision consists of the following (in thousands): For The Years Ended December 31, 2018 2017 Federal: Current $ - $ - Deferred - - State and local: Current - - Deferred - - Income tax provision $ - $ - For the years ended December 31, 2018 and 2017, the expected tax expense based on the federal statutory rate reconciled with the actual tax expense is as follows: For The Years Ended December 31, 2018 2017 U.S. federal statutory rate 21.00 % 34.00 % State tax rate, net of federal benefit 4.33 % 4.45 % Permanent differences - Change in fair value of warrant liability (0.08 )% 5.80 % - Other (0.05 )% (0.14 )% Adjustments to deferred taxes (27.61 )% (41.01 )% Tax Reform - Federal Rate Change 0.00 % (321.36 )% Tax Reform - Change in valuation allowance 0.00 % 321.36 % Change in valuation allowance 2.41 % (3.10 )% Income tax provision (0.00 )% 0.00 % The United States enacted the Tax Cuts and Jobs Act (“Act”) on December 22, 2017, most provisions of which took effect in years beginning after December 31, 2017. The Act made substantial changes to U.S. taxation of corporations, including a reduction in the U.S. federal corporate income tax rate from 34% to 21% and changes to limitations on the deductibility of executive compensation. The effect on deferred tax assets and liabilities of a change in law or tax rates is recognized in income in the period that includes the enactment date. After the enactment of the Act, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In our financial statements for the period ended December 31, 2017, we calculated an estimate of the impact of the Act related to the remeasurement of our net U.S. deferred tax asset due to the change in U.S. federal corporate income tax rate. The provisional amount recorded was deferred tax expense of $14.6 million, but which was fully and equally offset by a deferred tax benefit related to a corresponding reduction in our valuation allowance. In addition, due to changes in executive compensation rules pursuant to the Act, the Company determined that approximately $1.3 million of deferred tax asset for stock compensation may not be realizable. The Company had previously recorded a valuation allowance against the deferred tax asset so this adjustment had no impact on the financial statements for the period ended December 31, 2017. During the quarter ended December 31, 2018, the completed the accounting for the income tax effects of the Act, which resulted in an immaterial change in the net deferred tax asset, before valuation allowance, as of the enactment date. As of December 31, 2018 and 2017, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following (in thousands): As of December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 26,498 $ 29,580 Stock-based compensation 3,673 5,598 Goodwill and Tradename 29 32 Accruals 135 694 Transaction costs 214 39 Other 171 364 Total deferred tax assets 30,720 36,307 Valuation allowance (30,695 ) (30,864 ) Deferred tax assets, net of valuation allowance $ 25 $ 5,443 Deferred tax liabilities: Property and equipment (25 ) (65 ) Intangible assets - (5,378 ) Total deferred tax liabilities (25 ) (5,443 ) Net deferred tax liabilities $ - $ - For the years ended December 31, 2018 and 2017, the Company had approximately $ 102.6 114.6 In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2018 and December 31, 2017 because management has determined that it is more likely than not that these deferred tax assets will not be realized. The valuation allowance decreased by $0.2 million and decreased by $10.6 million during the years ended December 31, 2018 and December 31, 2017, respectively. Included in the current year decrease to the valuation allowance is a $0.1 million increase related to discontinued operations. Included in the prior year decrease to the valuation allowance is a $2.3 million decrease related to discontinued operations. The decrease in tax year ended December 31, 2018 is primarily related to impacts of the sale of assets to Celularity, offset by a reduction to stock compensation deferred tax asset associated with cancelled awards and utilization of net operating losses. The decrease in tax year ended December 31, 2017 is primarily related to the decrease in the corporate tax rate from 34% to 21% due to the enactment of the Act, offset by increases in net operating loss carryforwards.

Related Party

Related Party	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	16. Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director is a member of the Board of Directors. During the years ended December 31, 2018 and 2017, the Company incurred costs of approximately $0.26 million and $0.43 million, respectively, from this vendor. Approximately $0 and $0.123 million are included in accounts payable related to this related party as of December 31, 2018 and December 31, 2017, respectively.

Concentration of Risk

Concentration of Risk	12 Months Ended
	Dec. 31, 2018
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	17. Concentration of Risk During the year ended December 31, 2018, two customers accounted for 77% of the Company’s total net revenue from continuing operations, with Customer A accounting for 63% and Customer B accounting for 14%, respectively. During the year ended December 31, 2017, two customers accounted for 81% of the Company’s total net revenue from continuing operations with Customer A accounting for 65% and Customer B accounting for 16%, respectively. There were no customers exceeding 10% of its outstanding accounts receivable balance from continuing operations as of December 31, 2018. One customer accounted for 100% of its outstanding accounts receivable balance from continuing operations as of December 31, 2017

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	18. Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Impairment Goodwill and other indefinite-lived intangible assets are tested for impairment annually, at the end of the fourth quarter of each fiscal year, and between annual tests if an event occurs or circumstances change that would indicate it is more likely than not that the carrying amount may be impaired. Additionally, the Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, the present value of future cash flows, net of estimated operating costs, internal forecasts, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. These assumptions represent Level 3 inputs. Impairment of the Company’s goodwill for the year ended December 31, 2017 was $10.3 million. As a result of the AST with Celularity, all goodwill was written off as of May 7, 2018. Warrant Liabilities On December 31, 2017, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 210,000 shares of common stock as $130,000 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 73.37% risk-free rate of 2.09%, expected term of 4.07 years, and expected dividends of 0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $693,000 during the year ended December 31, 2017. The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the amended and restated Warrant. The amended and restated Warrant, as amended, is exercisable for 210,000 shares of the Company’s common stock at an exercise price of $4.70 per share. In connection with the amendments of January, March, April and June 2017, the Company recomputed the fair value of the original warrant and amended warrant using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 65.33%-78.98%, risk-free rate of 1.49%-1.95%, expected term of 3.34-5.00 years, and expected dividends of 0.00%. As a result, the Company recorded warrant modification expense of $803,000 during the year ended December 31, 2017, which represents the incremental value of the amended warrant as compared to the original warrant, both valued as of the respective amendment dates. The issuance of common stock in connection with the Private Placement and Public Offering triggered an adjustment to the exercise price of certain warrants originally issued in November 2012 from $55.10 per share to $5.00 per share to $4.00 per share with a corresponding adjustment to the number of shares underlying such warrants from 6,629 shares to 29,034 shares to 36,231 shares. The impact of such adjustment is included in the change in fair value of the warrant liabilities during the year ended December 31, 2017. On December 31, 2018, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 210,000 shares of common stock as $156,000 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 91.94% risk-free rate of 2.46%, expected term of 3.08 years, and expected dividends of 0.00%. During the year ended December 31, 2018, the Company recorded a loss on the change in fair value of these warrant liabilities of $26,000. Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer. The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Year Ended December 31, 2018 2017 Warrant Liabilities Beginning balance as of January 1, $ 130 $ 20 Change in fair value of warrant liability 26 (693 ) Warrant modification expense - 803 Ending balance as of December 31, $ 156 $ 130 Year Ended December 31, 2018 2017 Contingent Consideration Beginning balance as of January 1, $ - $ 1,816 Payments of contingent consideration - (1,851 ) Change in fair value of contingent consideration - 35 Ending balance as of December 31, $ - $ - Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): December 31, 2018 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 156 Total liabilities $ - $ - $ 156 December 31, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 130 Total liabilities $ - $ - $ 130

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	19. Defined Contribution Plan The Company maintains the Alliqua, Inc. 401(k) Profit Sharing Plan and Trust (“Plan”) in accordance with the provisions of Section 401(k) of the Code. The Plan covers substantially all full-time employees of the Company. Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code. Under this plan, the Company matches 50% of the employee’s contributions up to 6% of the employee’s annual compensation, as defined by the plan. Employees are eligible for the match after a six-month waiting period and the Company match vests immediately. The Company’s contribution to the plan was $0.033 million and $0.097 million for the years ended December 31, 2018 and 2017, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	20. Subsequent Events On January 9, 2019, On January 24, 2019, the Company filed the definitive proxy statement for the special shareholders meeting regarding the reverse merger with Adynxx.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates in the Financial Statements The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2018 and 2017 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings.
Receivables, Policy [Policy Text Block]	Trade Accounts Receivable Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowances for doubtful accounts is recorded based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was nominal for December 31, 2018 and 2017.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf life expiration dates for products. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.
Property, Plant and Equipment, Policy [Policy Text Block]	Improvements and Equipment Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the lesser of the lease term or the estimated useful life. Repairs and maintenance costs are expensed as incurred. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Goodwill and Other Indefinite-Lived Intangible Assets The Company records goodwill and other indefinite-lived assets in connection with business combinations. Goodwill, which represents the excess of acquisition cost over the fair value of the net tangible and intangible assets of acquired companies, is not amortized. Indefinite-lived assets are stated at fair value as of the date acquired in a business combination. The Company assesses the recoverability of goodwill and certain indefinite-lived intangible assets annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level. Under Financial Accounting Standards Board (“FASB”) guidance for goodwill and intangible assets, a reporting unit is defined as an operating segment or one level below the operating segment, called a component. However, two or more components of an operating segment will be aggregated and deemed a single reporting unit if the components have similar economic characteristics. The Company operates as one reporting unit. Authoritative accounting guidance allows the Company to first assess qualitative factors to determine whether it is necessary to perform the more detailed two-step quantitative goodwill impairment test. The Company performs the quantitative test if its qualitative assessment determined it is more likely than not that a reporting unit’s fair value is less than its carrying amount. The Company may elect to bypass the qualitative assessment and proceed directly to the quantitative test for any reporting unit or asset. The quantitative goodwill impairment test, if necessary, is a two-step process. The first step is to identify the existence of a potential impairment by comparing the fair value of a reporting unit (the estimated fair value of a reporting unit is usually calculated using a discounted cash flow model) with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, the reporting unit’s goodwill is considered not to be impaired and performance of the second step of the quantitative goodwill impairment test is unnecessary. However, if the carrying amount of a reporting unit exceeds its fair value, the second step of the quantitative goodwill impairment test is performed to measure the amount of impairment loss to be recorded, if any. The second step of the quantitative goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined using the same approach as employed when determining the amount of goodwill that would be recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of its assets and liabilities as if the reporting unit had been acquired in a business combination and the fair value was the purchase price paid to acquire the reporting unit. The Company proceeded directly to the quantitative analysis considering the consideration to be received and the assets to be sold under the APA. As a result of this test, the Company’s goodwill was determined to be impaired and an impairment charge of $10.3 million was recorded for the year ended December 31, 2017. As of May 7, 2018, as a result of completing the Celularity AST, the Goodwill and Intangible Assets have been disposed of. At December 31, 2017 the remaining recorded goodwill was $1,659,000, included in assets of discontinued operations – noncurrent on the consolidated balance sheet. The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017, are as follows (in thousands): Goodwill Balance as of $ 11,959 Impairment loss (10,300 ) Balance as of December 31, 2017 1,659 Disposal of Intangible Assets, Asset Sale (1,659 ) Balance as of December 31, 2018 $ 0
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long-Lived Assets Long-lived assets, such as property and equipment, and intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company’s long-lived intangible assets primarily consist of developed technology, customer lists/relationships, non-compete agreements, trade names and trademarks and are amortized ratably over a range of one to ten years which approximates customer attrition rate and technology obsolescence. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment is based on generally accepted valuation methodologies, as deemed appropriate. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, the present value of future cash flows, net of estimated operating costs, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. Due to the APA, the long-lived asset group related to the Purchased Assets were sold and otherwise disposed of significantly before the end of its previously estimated useful life. The Company, therefore, tested its long-lived assets for recoverability as of December 31, 2017. These long-lived assets consist of property, plant and equipment and intangible assets subject to amortization. The consideration under the APA for the sale of the long-lived assets approximate the net book value of these assets at December 31, 2017, therefore, no impairment charge was recorded for long-lived assets during the year ended December 31, 2017. There were no long-lived assets as of December 31, 2018, due to the Celularity AST.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Cost of Goods Sold and Selling, General and Administrative Expenses Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature.
Shipping and Handling Costs [Policy Text Block]	Shipping and Handling Amounts billed to customers for shipping and handling are included in revenues. The related shipping and freight charges incurred by the Company are included in cost of goods sold and were not material for either the years ended December 31, 2018 or 2017.
Research and Development Expense, Policy [Policy Text Block]	Business Development The Company accounts for costs due to professional fees, including accounting, legal and consulting fees related to business developments; in the past these were in other expenses and professional fees as part of general and administrative expenses, however because they are not of a normal course of business, these have been reclassified and presented separately within the Company’s statement of operations. During the year ended December 31, 2018, we incurred business development costs of $1.0 million and during the year ended December 31, 2017, we received a benefit of $0.366 million in development due, in part, to the repayment of a portion of the bridge loan to Soluble Systems, LLC that had been previously written off at the time the proposed transaction was terminated.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes pursuant to the asset and liability method which requires us to recognize current tax liabilities or receivables for the amount of taxes the Company estimate are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2018 and 2017. As of December 31, 2018 and December 31, 2017, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
Common Stock Purchase Warrant [Policy Text Block]	Common Stock Purchase Warrants The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required. The Company’s free-standing derivatives consist of warrants to purchase common stock that were issued pursuant to a Securities Purchase Agreement on November 8, 2012 (which expired in November 2017) and pursuant to a Credit Agreement on May 29, 2015. The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions. Accordingly, the outstanding portions of these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2018 and 2017. The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, "Leases (Topic 842)." ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements" in July 2018, and ASU No. 2018-20 "Leases (Topic 842) - Narrow Scope Improvements for Lessors" in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company expects to adopt ASU 2016-02 effective January 1, 2019, upon adoption of Topic 842, the Company expects recognition of additional assets and corresponding liabilities pertaining to its operating leases on its consolidated balance sheets. The Company does not expect the adoption of the new standard to have a significant impact on its consolidated statements of operations and cash flows. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement”. The amendments in this update is to improve the effectiveness of disclosures in the notes to the financial statements by facilitating clear communication of the information required by GAAP that is most important to users of each entity’s financial statements. The amendments in this Update apply to all entities that are required, under existing GAAP, to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”. The amendments in this update is to maintain or improve the usefulness of the information provided to the users of financial statements while reducing cost and complexity in financial reporting. The areas for simplification in this Update involve several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. On December 22, 2017 the U.S. government enacted significant changes to federal tax law following the passage of the Tax Cuts and Jobs Act (“the Act”). Following the enactment of the Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”). The Company follows the guidance in SAB 118, which provides additional clarification regarding the application of US GAAP in situations where the Company does not have the necessary information available, prepared, or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Act for the reporting period in which the Act was enacted. SAB 118 provides for a measurement period beginning in the reporting period that includes the Act’s enactment date and ending when the Company has obtained, prepared, and analyzed the information needed in order to complete the accounting requirements but in no circumstances should the measurement period extend beyond one year from the enactment date. During the quarter ended December 31, 2018, the Company completed the accounting for the income tax effects of the Act, which resulted in an immaterial change in the net deferred tax asset, before valuation allowance, as of the enactment date. These impacts are disclosed in “Note 15 – Income Taxes” in the Notes accompanying the audited Consolidated Financial Statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The Company adopted ASU 2017-09 during the year ended December 31, 2018, In January 2017, the FASB issued ASU 2017-01 “Business Combinations (Topic 805): Clarifying the Definition of a Business”, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company adopted ASU 2017-01 during the year ended December 31, 2018, and the adoption did not have a material impact on its financial statements. In December 2016, the FASB issued ASU 2016-18 “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force,” which clarifies the presentation requirements of restricted cash within the statement of cash flows. The changes in restricted cash and restricted cash equivalents during the period should be included in the beginning and ending cash and cash equivalents balance reconciliation on the statement of cash flows. When cash, cash equivalents, restricted cash or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity shall calculate a total cash amount in a narrative or tabular format that agrees to the amount shown on the statement of cash flows. Details on the nature and amounts of restricted cash should also be disclosed. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company adopted ASU 2016-18 during the year ended December 31, 2018 In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduce the current diversity in practice. ASU No. 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017, with early application permitted. This guidance is applicable to the Company’s fiscal year beginning January 1, 2018. The Company has adopted ASU 2016-15 during the year ended December 31, 2018, In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company has adopted ASU 2016-09 during the year ended December 31, 2018, In May 2014 the FASB issued Accounting Standards No. 2014-09, Revenue from Contracts with Customers (Topic 606), in May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606)—Narrow Scope Improvements and Practical Expedients These standards and their effect on the Company’s consolidated financial statements and related disclosures are discussed below under Note 4, Revenue Recognition.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Goodwill [Table Text Block]	The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017, are as follows (in thousands): Goodwill Balance as of $ 11,959 Impairment loss (10,300 ) Balance as of December 31, 2017 1,659 Disposal of Intangible Assets, Asset Sale (1,659 ) Balance as of December 31, 2018 $ 0

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: As of December 31, 2018 2017 Stock options 375,591 809,586 Warrants 276,478 478,330 Non-vested restricted stock 20,000 189,674 Total 672,069 1,477,590

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of discontinued operations for the years ended December 31, 2018 and 2017 are presented in the following table (in thousands): Year Ended December 31, 2018 2017 Revenue, net of returns, allowances and discounts $ 6,681 $ 18,790 Cost of revenues 1,791 5,319 Gross profit 4,890 13,471 Selling, general and administrative 11,179 34,488 Other income - (200 ) Interest expense 612 2,282 Warrant modification expense - 803 Deferred income tax benefit - (743 ) Loss from discontinued operations, net of tax (6,901 ) (23,159 ) Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands): December 31, December 31, 2018 2017 Accounts receivable, net $ 60 $ 3,161 Inventory, net - 1,458 Prepaid expenses and other current assets - 443 Total current assets 60 5,062 Fixed assets, net - 1,041 Intangible assets, net - 22,069 Goodwill, net - 1,659 Total assets of discontinued operations 60 29,831 Accounts payable 271 957 Accrued expenses and other current liabilities - 3,557 Senior secured term loan, net - 10,929 Total current liabilities $ 271 $ 15,443 Other long-term liabilities - 245 Total liabilities of discontinued operations $ 271 $ 15,688
Schedule of Gain Loss on Disposal of Discontinued Operations [Table Text Block]	During the year ended December 31, 2018, the Company recorded a net gain of approximately $5.5 million (net of state income tax of $0.546 million) on the sale of the assets related to the purchase agreement with Celularity, as shown in the following table (in thousands): Proceeds from sale Total Consideration 29,000 Less: Net book value of assets sold to Celularity Inventory, net (1,578 ) Intangibles, net (20,557 ) Goodwill (1,659 ) Fixed Assets, net (904 ) Other current assets 15 Total net book value of assets (24,683 ) Add: Net book value of liabilities extinguished due to sale Milestone payment 1,000 Other liabilities 717 Total net book value of liabilities 1,717 Less: State tax expense (546 ) Net gain on sale of assets $ 5,488 During the year ended December 31, 2017, the Company recorded a gain of approximately $1.7 million (net of tax of $ 0 Proceeds from sale Consideration for inventory $ 112 Consideration for intangible assets 3,600 Total Consideration 3,712 Less: Net book value of assets sold to Argentum Inventory, net (307 ) Intangibles, net (1,709 ) Total net book value of assets (2,016 ) Gain on sale of assets $ 1,696

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following (dollars in thousands): December 31, December 31, 2018 2017 Raw materials $ 101 $ 98 Less: Inventory reserve for excess and slow moving inventory - (5 ) Total $ 101 $ 93

Improvements and Equipment, n_2

Improvements and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Improvements and equipment consist of the following (in thousands): December 31, Useful Life 2018 2017 (Years) Machinery and equipment 3-10 $ 2,893 $ 2,893 Office furniture and equipment 3-10 49 56 Leasehold improvements (A) 228 228 3,170 3,177 Less: Accumulated depreciation and amortization (2,970 ) (2,655 ) Improvements and equipment, net $ 200 $ 522 (A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities consist of the following (in thousands): December 31, December 31, 2018 2017 Salaries, benefits and incentive compensation $ 108 $ 509 Professional fees 230 176 Other 47 27 Total accrued expenses and other current liabilities $ 385 $ 712

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2018
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases at December 31, 2018 are as follows (in thousands): Gross Lease Payments Sublet Lease Payments Net Lease Payments 2019 $ 430 $ 223 $ 207 2020 434 227 207 2021 439 232 207 2022 443 236 207 2023 287 80 207 Thereafter 434 - 434 Total $ 2,467 $ 998 $ 1,469

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Schedule of Nonvested Share Activity [Table Text Block]	A summary of restricted stock award activity during the years ended December 31, 2018 and 2017 is presented below (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Total Grant Date Fair Value Non-vested, December 31, 2016 147 $ 26.26 $ 3,862 Granted 182 3.41 621 Vested (137 ) 17.35 (2,373 ) Forfeited (2 ) 3.87 (10 ) Non-vested, December 31, 2017 190 $ 11.07 $ 2,100 Granted 20 1.96 39 Vested (185 ) 11.07 (2,045 ) Forfeited (5 ) 11.07 (55 ) Non-vested, December 31, 2018 20 $ 1.96 $ 39
Warrant [Member]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to warrants at December 31, 2018 (in thousands, except years and per warrant data): Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Number of Warrants Weighted Average Remaining Life in Years Exercisable Number of Warrants $4.40 - $39.99 233 3.1 233 $40.00 - $105.00 43 0.3 43 276 2.4 276
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the warrant activity during the years ended December 31, 2018 and 2017 is presented below (in thousands, except years and per warrant data): Number of Warrants Weighted Average Exercise Price per Warrant Weighted Average Remaining Life in Years Intrinsic Value Outstanding, December 31, 2016 337 $ 56.90 Issued 159 4.66 Adjustment for price reset 29 Exercised - - Forfeited (47 ) 9.35 Outstanding, December 31, 2017 478 $ 32.79 $ - Issued - - Exercised - - Cancelled (202 ) 50.03 Outstanding, December 31, 2018 276 $ 20.20 2.7 $ - Exercisable, December 31, 2018 276 $ 20.20 2.7 $ -
Employee Stock Option [Member]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	As a result, a summary of the Company’s outstanding and exercisable options as of December 31, 2018 was as follows (in thousands, except years and per option data): Options Outstanding Options Exercisable Range of Exercise Price Weighted Average Exercise Price Outstanding Number of Options Weighted Average Exercise Price Weighted Average Remaining Life in Years Exercisable Number of Options $2.00 - $4.00 $ 3.64 52 3.64 8.5 52 $4.10 - $9.90 8.72 23 8.72 7.4 23 $10.00 - $19.90 10.50 8 10.50 7.2 8 $20.00 - $39.90 33.47 40 33.47 4.4 40 $40.00 - $49.90 44.54 33 44.54 3.3 33 $50.00 - $59.90 53.87 26 53.87 1.2 26 $60.00 - $69.90 65.91 152 65.91 3.6 152 $70.00 - $79.90 79.40 1 79.40 5.3 1 $80.00 - $89.90 87.50 18 87.50 2.2 18 $90.00 - $99.90 90.00 18 90.00 2.1 18 $100.00 - $266.90 109.40 5 109.40 1.4 5 49.29 376 49.29 4.3 376
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: Year Ended December 31, 2018 2017 Risk free interest rate N/A 1.81%-2.43 % Expected term (years) N/A 5.04-6.50 Expected volatility N/A 81.94% - 87.00 % Expected dividends N/A 0.00 %
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the years ended December 31, 2018 and 2017 is presented below (in thousands, except years and per option data): Number of Options Weighted Average Exercise Price per Option Weighted Average Remaining Life in Years Intrinsic Value Outstanding, December 31, 2016 720 $ 52.90 Granted 258 3.53 Exercised - - Forfeited (168 ) 40.60 Outstanding, December 31, 2017 810 $ 39.67 Granted - - Exercised - - Forfeited (434 ) 31.42 Outstanding, December 31, 2018 376 $ 49.29 4.3 $ - Exerciseable, December 31, 2018 376 $ 49.29 4.3 $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The income tax (benefit) provision consists of the following (in thousands): For The Years Ended December 31, 2018 2017 Federal: Current $ - $ - Deferred - - State and local: Current - - Deferred - - Income tax provision $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the years ended December 31, 2018 and 2017, the expected tax expense based on the federal statutory rate reconciled with the actual tax expense is as follows: For The Years Ended December 31, 2018 2017 U.S. federal statutory rate 21.00 % 34.00 % State tax rate, net of federal benefit 4.33 % 4.45 % Permanent differences - Change in fair value of warrant liability (0.08 )% 5.80 % - Other (0.05 )% (0.14 )% Adjustments to deferred taxes (27.61 )% (41.01 )% Tax Reform - Federal Rate Change 0.00 % (321.36 )% Tax Reform - Change in valuation allowance 0.00 % 321.36 % Change in valuation allowance 2.41 % (3.10 )% Income tax provision (0.00 )% 0.00 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2018 and 2017, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following (in thousands): As of December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 26,498 $ 29,580 Stock-based compensation 3,673 5,598 Goodwill and Tradename 29 32 Accruals 135 694 Transaction costs 214 39 Other 171 364 Total deferred tax assets 30,720 36,307 Valuation allowance (30,695 ) (30,864 ) Deferred tax assets, net of valuation allowance $ 25 $ 5,443 Deferred tax liabilities: Property and equipment (25 ) (65 ) Intangible assets - (5,378 ) Total deferred tax liabilities (25 ) (5,443 ) Net deferred tax liabilities $ - $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Year Ended December 31, 2018 2017 Warrant Liabilities Beginning balance as of January 1, $ 130 $ 20 Change in fair value of warrant liability 26 (693 ) Warrant modification expense - 803 Ending balance as of December 31, $ 156 $ 130 Year Ended December 31, 2018 2017 Contingent Consideration Beginning balance as of January 1, $ - $ 1,816 Payments of contingent consideration - (1,851 ) Change in fair value of contingent consideration - 35 Ending balance as of December 31, $ - $ -
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): December 31, 2018 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 156 Total liabilities $ - $ - $ 156 December 31, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 130 Total liabilities $ - $ - $ 130

Description of Business and B_2

Description of Business and Basis of Presentation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	May 07, 2018	Oct. 05, 2017	Dec. 31, 2018	Nov. 27, 2018	Oct. 11, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration			$ 3,600
Common Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001	$ 0.001
Maximum Amount Of Permitted Financing					$ 10,000
Stockholders' Equity, Reverse Stock Split		1-for-10
TOP [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Method Investment, Ownership Percentage				90.00%
Maximum Amount Of Permitted Financing				$ 10,000
Adynxx [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Termination Fee Payable					$ 249
Post Merger Period [Member] | Adynxx [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Method Investment, Ownership Percentage					86.00%
Pre Merger Period [Member] | Adynxx [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Method Investment, Ownership Percentage					14.00%
Celularity, Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 29,000
Perceptive Credit Holdings LP [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of Debt			$ 14,800
Perceptive Credit Holdings LP [Member] | Adynxx [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of Debt	$ 14,800

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Balance	$ 1,659	$ 11,959
Impairment Loss		(10,300)
Disposal of Intangible Assets, Asset Sale	(1,659)
Balance	$ 0	$ 1,659

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Total Impairments, Goodwill		$ 10,300
Goodwill	$ 0	1,659	$ 11,959
Business Development	$ 1,000
Bridge Loan		$ 366

Liquidity (Details Textual)

Liquidity (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net Income (Loss) Attributable to Parent	$ (8,417)	$ (25,707)
Net Cash Provided by (Used in) Operating Activities	(9,710)	(10,672)
Cash and Cash Equivalents, at Carrying Value	8,880	$ 2,181	$ 5,580
Business Combination, Consideration Transferred	158,400
Proceeds from Lines of Credit	29,000
Perceptive Credit Holdings LP [Member]
Repayments of Debt	$ 14,800

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	672,069	1,477,590
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	375,591	809,586
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	276,478	478,330
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,000	189,674

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue, net of returns, allowances and discounts	$ 6,681	$ 18,790
Cost of revenues	1,791	5,319
Gross profit	4,890	13,471
Selling, general and administrative	11,179	34,488
Other income	0	(200)
Interest expense	612	2,282
Warrant modification expense	0	803
Deferred income tax benefit	0	(743)
Loss from discontinued operations, net of tax	$ (6,901)	$ (23,159)

Discontinued Operations (Deta_2

Discontinued Operations (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Proceeds from sale
Total Consideration	$ 29,000	$ 3,712
Less: Net book value of assets sold to Celularity
Inventory, net	(1,578)	(307)
Intangibles, net	(20,557)	(1,709)
Goodwill	(1,659)
Fixed Assets, net	(904)
Other current assets	15
Total net book value of assets	(24,683)	(2,016)
Add: Net book value of liabilities extinguished due to sale
Milestone payment	1,000
Other liabilities	717
Total net book value of liabilities	1,717
Less: State tax expense	500	0
Net gain on sale of assets	$ (5,488)	$ (1,696)

Discontinued Operations (Deta_3

Discontinued Operations (Details 2) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	$ 60	$ 3,161
Inventory, net	0	1,458
Prepaid expenses and other current assets	0	443
Total current assets	60	5,062
Intangible assets, net	0	22,069
Fixed assets, net	0	1,041
Goodwill, net	0	1,659
Total assets of discontinued operations	60	29,831
Accounts payable	271	957
Accrued expenses and other current liabilities	0	3,557
Senior secured term loan, net	0	10,929
Total current liabilities	271	15,443
Other long-term liabilities	0	245
Total liabilities of discontinued operations	$ 271	$ 15,688

Discontinued Operations (Deta_4

Discontinued Operations (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Proceeds from sale
Consideration for inventory		$ 112
Consideration for intangible assets		3,600
Total Consideration	$ 29,000	3,712
Less: Net book value of assets sold to Argentum
Inventory, net	(1,578)	(307)
Intangibles, net	(20,557)	(1,709)
Total net book value of assets	(24,683)	(2,016)
Gain on sale of assets	$ 5,488	$ 1,696

Discontinued Operations (Deta_5

Discontinued Operations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Aug. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	$ 5,488,000	$ 1,696,000
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	500,000	0
Disposal Group, Including Discontinued Operation, Consideration	3,600,000
Disposal Group, Including Discontinued Operation, Maximum Amount To be Received for Unsold Inventory	112,000
Disposal Group, Including Discontinued Operation, Escrow Deposit, Current	300,000
Accrued Fees and Other Revenue Receivable			$ 200,000
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of Intangible Assets	1,400,000	4,400,000
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	$ 5,500,000	$ 1,700,000

Termination of Merger Agreeme_2

Termination of Merger Agreement (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 27, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 13, 2018	Jan. 30, 2017	Dec. 31, 2016	Oct. 05, 2016
Proceeds From Bridge Loan	$ 1,000,000	$ 0	$ 1,000,000
Business Combinations Acquisition Related Costs Other			285,000
Bridge Loan [Member]
Long-term Debt, Gross							$ 1,400,000
Business Combination, Acquisition Related Costs			365,000
Debt Instrument, Face Amount				$ 2,000,000	$ 400,000	$ 1,000,000
Allowance for Doubtful Accounts Receivable, Recoveries			$ 650,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Raw materials	$ 101	$ 98
Less: Inventory reserve for excess and slow moving inventory	0	(5)
Total	$ 101	$ 93

Improvements and Equipment, n_3

Improvements and Equipment, net (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Machinery and equipment		$ 2,893	$ 2,893
Office furniture and equipment		49	56
Leasehold improvements	[1]	228	228
Property, Plant and Equipment, Gross, Total		3,170	3,177
Less: Accumulated depreciation and amortization		(2,970)	(2,655)
Improvements and equipment, net		$ 200	$ 522
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		10 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		10 years
[1]	Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Improvements and Equipment, n_4

Improvements and Equipment, net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization	$ 315	$ 315

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 108	$ 509
Professional fees	230	176
Other	47	27
Total accrued expenses and other current liabilities	$ 385	$ 712

Operating Leases (Details)

Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Gross Lease Payments [Abstract]
2,019	$ 430
2,020	434
2,021	439
2,022	443
2,023	287
Thereafter	434
Total	2,467
Sublet Lease Payments [Abstract]
2,019	223
2,020	227
2,021	232
2,022	236
2,023	80
Thereafter	0
Total	998
Net Lease Payments [Abstract]
2,019	207
2,020	207
2,021	207
2,022	207
2,023	207
Thereafter	434
Total	$ 1,469

Operating Leases (Details Textu

Operating Leases (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Sublet [Member]
Operating Leased Assets [Line Items]
Lease Income	$ 154
Langhorne [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	207	$ 207
Yardley [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$ 230	$ 218

Debt (Details Textual)

Debt (Details Textual) - USD ($)	May 07, 2018	Mar. 13, 2018	Aug. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Oct. 11, 2018	Jun. 01, 2017	Jan. 30, 2017	Dec. 31, 2016	May 29, 2015	Nov. 30, 2012
Debt Instrument [Line Items]
Gain (Loss) on Extinguishment of Debt				$ (1,706,000)	$ (182,000)
Amortization of Debt Discount (Premium)				$ 254,000	$ 824,000
Debt Instrument, Fee Amount	$ 200,000
Common Stock Purchased By Warrants Issued				75,000
Common Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 55.138			$ 4.70				$ 55.10
Derivative Liability				$ 156,000	$ 130,000				$ 20,000
Discontinued Operations [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)				178,000	577,000
Warrant [Member]
Debt Instrument [Line Items]
Derivative Liability				2,700,000
Perceptive Credit Holdings LP [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 14,800,000
Repayments of Debt				$ 14,800,000
Bridge Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 2,000,000						$ 400,000	$ 1,000,000
Debt Instrument, Interest Rate Terms		The BLN bore interest at a rate per annum equal to the sum of (i) the greater of (x) LIBOR and (y) 1%, plus (ii) an applicable margin of 9.75%.
Upfront Fee Payable		$ 250,000
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 15,500,000
Proceeds from Divestiture of Businesses and Interests in Affiliates			$ 1,650,000
Repayments of Debt			1,618,000
Payments For Prepayment Penalties			$ 32,000
Write off of Deferred Debt Issuance Cost					53,000
Prepayment Penalty On Early Extinguishment Of Debt					32,000
Amortization of Debt Discount (Premium)					$ 129,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jul. 15, 2011	Apr. 30, 2018	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Commitments And Contingencies [Line Items]
Accrued Liabilities, Current					$ 385,000	$ 712,000
Revenues					2,216,000	2,019,000
Litigation Settlement, Expense		$ 125,000
CellularityInc [Member]
Commitments And Contingencies [Line Items]
Royalty Expense					381,000	818,000
Accrued Liabilities, Current					$ 0	$ 227,000
Choice TherapeuticsInc [Member]
Commitments And Contingencies [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				132,000
Business Combination, Contingent Consideration, Liability				$ 500,000
Installment Two [Member]
Commitments And Contingencies [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets			3.5
Installment Two [Member] | Two Thousand Fifteen Mist Therapy [Member]
Commitments And Contingencies [Line Items]
Revenues			$ 10,500,000
Installment Two [Member] | Two Thousands Sixteen Mist Therapy [Member]
Commitments And Contingencies [Line Items]
Revenues			10,200,000
Installment Two [Member] | Contingent Consideration [Member]
Commitments And Contingencies [Line Items]
Payments to Acquire Businesses, Gross			$ 675,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			101,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			$ 675,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value, Granted (in dollars per share)		$ 2.49
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Non-vested, December 31 (in shares)	190	147
Number of Shares, Granted (in shares)	20	182
Number of Shares, Vested (in shares)	(185)	(137)
Number of Shares, Forfeited (in shares)	(5)	(2)
Number of Shares, Non-vested, December 31 (in shares)	20	190
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)		$ 26.26
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	$ 1.96	3.41
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	11.07	17.35
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	11.07	3.87
Weighted Average Grant Date Fair Value, Non-vested, December 31 (in dollars per share)	$ 1.96	$ 11.07
Total Grant Date Fair Value, Non-vested, December 31	$ 2,100	$ 3,862
Total Grant Date Fair Value, Granted	39	621
Total Grant Date Fair Value, Vested	(2,045)	(2,373)
Total Grant Date Fair Value, Forfeited	(55)	(10)
Total Grant Date Fair Value, Non-vested, December 31	$ 39	$ 2,100

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - Warrant [Member] - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	478	337
Number of Warrants, Issued (in shares)	0	159
Number of Warrants, Adjustment for price reset (in shares)		29
Number of Warrants, Exercised (in shares)	0	0
Number of Options, Forfeited (in shares)	(202)	(47)
Number of Options, Outstanding at End of the period (in shares)	276	478
Number of Warrants, Exercisable, December 31, 2017 (in shares)	276
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 32.79	$ 56.90
Weighted Average Exercise Price, Issued (in dollars per share)	0	4.66
Weighted Average Exercise Price, Exercised (in dollars per share)	0	0
Weighted Average Exercise Price, Cancelled (in dollars per share)	50.03	9.35
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	20.20	$ 32.79
Weighted Average Exercise Price, Exercisable December 31, 2017 (in dollars per share)	$ 20.20
Weighted Average Remaining Life In Years, Outstanding, December 31, 2018 (Years)	2 years 8 months 12 days
Weighted Average Remaining Life In Years, Exercisable, December 31, 2018 (Years)	2 years 8 months 12 days
Intrinsic Value, Outstanding	$ 0	$ 0
Intrinsic Value, Exercisable, December 31, 2018	$ 0

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) shares in Thousands	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Warrants	276
Weighted Average Remaining Life in Years	2 years 4 months 24 days
Exercisable Number of Warrants	276
Exercise Price Range $4.40 - $39.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Warrants	233
Weighted Average Remaining Life in Years	3 years 1 month 6 days
Exercisable Number of Warrants	233
Exercise Price Range $4.40 - $39.99 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 39.99
Exercise Price Range $4.40 - $39.99 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.40
Exercise Price Ranage $40.00 - $105.0 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Warrants	43
Weighted Average Remaining Life in Years	3 months 18 days
Exercisable Number of Warrants	43
Exercise Price Ranage $40.00 - $105.0 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 105
Exercise Price Ranage $40.00 - $105.0 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 40

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.00%
Expected term (years)	0 years
Expected volatility	0.00%
Expected dividends	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.81%
Expected term (years)		5 years 14 days
Expected volatility		81.94%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		2.43%
Expected term (years)		6 years 6 months
Expected volatility		87.00%

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4) - Employee Stock Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	810	720
Number of Options, Granted (in shares)	0	258
Number of Options, Exercised (in shares)	0	0
Number of Options, Forfeited (in shares)	(434)	(168)
Number of Options, Outstanding at End of the period (in shares)	376	810
Number of Options, Exerciseable, December 31, 2018 (in shares)	376
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 39.67	$ 52.90
Weighted Average Exercise Price, Granted (in dollars per share)	0	3.53
Weighted Average Exercise Price, Exercised (in dollars per share)	0	0
Weighted Average Exercise Price, Forfeited (in dollars per share)	31.42	40.60
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	49.29	$ 39.67
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 49.29
Weighted Average Remaining Life In Years, Outstanding, December 31, 2018 (Years)	4 years 3 months 18 days	0 years
Weighted Average Remaining Life In Years, Exercisable, December 31, 2018 (Years)	4 years 3 months 18 days
Intrinsic Value, Outstanding, December 31, 2018	$ 0
Intrinsic Value,Exerciseable, December 31, 2018	$ 0

Stockholders' Equity (Details 5

Stockholders' Equity (Details 5) shares in Thousands	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 90
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$ 99.90
Options Outstanding, Outstanding Number of Options (in shares) | shares	276
Options Exercisable, Exercisable Number of Options (in shares) | shares	276
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 49.29
Options Outstanding, Outstanding Number of Options (in shares) | shares	376
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 49.29
Options Exercisable, Weighted Average Remaining Life in Years (in years)	4 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	376
Exercise Price Range 2.00 - 4.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 2
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	4
Exercise Price Range 2.00 - 4.00 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 3.64
Options Outstanding, Outstanding Number of Options (in shares) | shares	52
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 3.64
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 6 months
Options Exercisable, Exercisable Number of Options (in shares) | shares	52
Exercise Price Range 4.10 - 9.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 4.10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	9.90
Exercise Price Range 4.10 - 9.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 8.72
Options Outstanding, Outstanding Number of Options (in shares) | shares	23
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 8.72
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	23
Exercise Price Range 10.00 - 19.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	19.90
Exercise Price Range 10.00 - 19.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 10.50
Options Outstanding, Outstanding Number of Options (in shares) | shares	8
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 10.50
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	8
Exercise Price Range 20.00 - 39.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 20
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	39.90
Exercise Price Range 20.00 - 39.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 33.47
Options Outstanding, Outstanding Number of Options (in shares) | shares	40
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 33.47
Options Exercisable, Weighted Average Remaining Life in Years (in years)	4 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	40
Exercise Price Range 40.00 - 49.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 40
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	49.90
Exercise Price Range 40.00 - 49.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 44.54
Options Outstanding, Outstanding Number of Options (in shares) | shares	33
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 44.54
Options Exercisable, Weighted Average Remaining Life in Years (in years)	3 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	33
Exercise Price Range 50.00 - 59.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 0
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	59.90
Exercise Price Range 50.00 - 59.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 53.87
Options Outstanding, Outstanding Number of Options (in shares) | shares	26
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 53.87
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	26
Exercise Price Range 60.00 - 69.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 60
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	69.90
Exercise Price Range 60.00 - 69.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 65.91
Options Outstanding, Outstanding Number of Options (in shares) | shares	152
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 65.91
Options Exercisable, Weighted Average Remaining Life in Years (in years)	3 years 7 months 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	152
Exercise Price Range 70.00 - 79.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 70
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	79.90
Exercise Price Range 70.00 - 79.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 79.40
Options Outstanding, Outstanding Number of Options (in shares) | shares	1
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 79.40
Options Exercisable, Weighted Average Remaining Life in Years (in years)	5 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	1
Exercise Price Range 80.00 - 89.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 80
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	89.90
Exercise Price Range 80.00 - 89.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 87.50
Options Outstanding, Outstanding Number of Options (in shares) | shares	18
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 87.50
Options Exercisable, Weighted Average Remaining Life in Years (in years)	2 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	18
Exercise Price Range 90.00 - 99.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 90
Options Outstanding, Outstanding Number of Options (in shares) | shares	18
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 90
Options Exercisable, Weighted Average Remaining Life in Years (in years)	2 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	18
Exercise Price Range 100.00 - 266.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 100
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	266.90
Exercise Price Range 100.00 - 266.90 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 109.40
Options Outstanding, Outstanding Number of Options (in shares) | shares	5
Weighted Average Exercise Price, Exerciseable, December 31, 2018 (in dollars per share)	$ 109.40
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	5

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Apr. 03, 2017	Feb. 27, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Oct. 11, 2018	Jun. 23, 2017	Jun. 01, 2017	Dec. 31, 2016	Nov. 30, 2012	Nov. 08, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 1,000,000	$ 2,000,000
Preferred Stock, Shares Authorized			1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share			$ 0.001	$ 0.001
Proceeds from Issuance of Private Placement		$ 2,800,000
Common Stock, Par or Stated Value Per Share			0.001	$ 0.001		$ 0.001
Stock Issued During Period, Value, New Issues				$ 5,849,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								210,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 55.138					$ 4.70		$ 55.10
Derivative Liability			$ 156,000	$ 130,000					$ 20,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 2.49
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based Compensation Arrangement By Share based Payment Award Fair Value Assumptions Fore feiture Rate			5.00%	5.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based Compensation Arrangement By Share based Payment Award Fair Value Assumptions Fore feiture Rate			0.00%	0.00%
Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			182,857
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			54,131
Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			950,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			434,616
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				400,000	350,000
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 30,000	$ 45,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 970,000	$ 2,000,000
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues		554,000		38,072
Share Price		$ 5
Payments for Other Fees		$ 196,000
Payment for Administrative Fees		$ 40,000
Under written Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues	947,325
Share Price	$ 4										$ 4
Payments for Other Fees	$ 365,000
Payment for Administrative Fees	92,000
Stock Issued During Period, Value, New Issues	$ 3,800,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	23,686
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.40										$ 21.90
Derivative Liability	$ 78,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues				1,639,825
Common Stock, Capital Shares Reserved for Future Issuance							100,428
Stock Issued During Period, Value, New Issues				$ 2,000
Non Executive Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				258,105
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 642,000
Non Executive Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				5.70
Non Executive Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 2.09
Non Executive Employees [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number				45,045
Non Executive Employees [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number				213,060
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			20,000	182,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 1.96	$ 3.41
Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				66,936
Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				5,000
Restricted Stock [Member] | Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				50,000
Restricted Stock [Member] | Deferred Compensation, Share-based Payments [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				60,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			39,200	621,000
Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Grant Date Fair Value			$ 20,000	$ 181,936
November 2012 Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	36,231

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Federal:
Current	$ 0	$ 0
Deferred	0	0
State and local:
Current	0	0
Deferred	0	0
Income tax provision	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
U.S. federal statutory rate	21.00%	34.00%
State tax rate, net of federal benefit	4.33%	4.45%
Permanent differences
- Change in fair value of warrant liability	(0.08%)	5.80%
- Other	(0.05%)	(0.14%)
Adjustments to deferred taxes	(27.61%)	(41.01%)
Tax Reform - Federal Rate Change	0.00%	(321.36%)
Tax Reform - Change in valuation allowance	0.00%	321.36%
Change in valuation allowance	2.41%	(3.10%)
Income tax provision	(0.00%)	0.00%

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 26,498	$ 29,580
Stock-based compensation	3,673	5,598
Goodwill and Tradename	29	32
Accruals	135	694
Transaction costs	214	39
Other	171	364
Total deferred tax assets	30,720	36,307
Valuation allowance	(30,695)	(30,864)
Deferred tax assets, net of valuation allowance	25	5,443
Deferred tax liabilities:
Property and equipment	(25)	(65)
Intangible assets	0	(5,378)
Total deferred tax liabilities	(25)	(5,443)
Net deferred tax liabilities	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount	$ 14.6
Unrecognised Deferred Tax Asstes Stock Compensation	1.3
Increase Decrease In Net Operating Loss Carry forwards			$ 4.8
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	0.2	$ 10.6
Valuation Allowance Deferred Tax Asset Increase Decrease Related To Discontinued Operations Amount	0.1	2.3
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 102.6	114.6
Scenario, Plan [Member]
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Acquisition Of CellerationInc [Member] | Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards		47.9	$ 47.9
Choice TherapeuticsInc [Member] | Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 2.5	2.5
Pennsylvania [Member] | State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	23.5	26.4
Florida [Member] | State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 11.1	$ 11.3

Related Party (Details Textual)

Related Party (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 260	$ 430
Accounts Payable, Related Parties	$ 0	$ 123

Concentration of Risk (Details

Concentration of Risk (Details Textual)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Sales Revenue, Net [Member]
Concentration Risk, Percentage	77.00%	81.00%
Sales Revenue, Net [Member] | Customer A [Member]
Concentration Risk, Percentage	63.00%	65.00%
Sales Revenue, Net [Member] | Customer B [Member]
Concentration Risk, Percentage	14.00%	16.00%
Accounts Receivable [Member]
Concentration Risk, Percentage	10.00%
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage		100.00%

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 130	$ 20
Change in fair value of warrant liability	26	(693)
Warrant modification expense	0	803
Ending balance	156	130
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	0	1,816
Payments of contingent consideration	0	(1,851)
Change in fair value of warrant liability	0	35
Ending balance	$ 0	$ 0

Fair Value Measurement (Detai_2

Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Liabilities:
Warrant liabilities	$ 156	$ 130	$ 20
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	156	130
Total liabilities	$ 156	$ 130

Fair Value Measurement (Detai_3

Fair Value Measurement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jun. 01, 2017	Dec. 31, 2016	Nov. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 156	$ 130		$ 20
Fair Value Adjustment of Warrants	$ 26	$ (692)
Fair Values Assumptions Expected Term 1		4 years 25 days
Fair Value Assumptions Expected Rates	0.00%
Asset Impairment Charges	$ 0	$ 10,300
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			210,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 55.138		$ 4.70		$ 55.10
Restructuring Costs	$ 0	803
Class of Warrant or Right, Outstanding					6,629
Maximum [Member] | Private Placement 2017 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 4
Class of Warrant or Right, Outstanding					36,231
Minimum [Member] | Private Placement 2017 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5
Class of Warrant or Right, Outstanding					29,034
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 156	$ 130
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock	210,000	210,000
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Values Assumptions Expected Term 1	3 years 29 days
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Values Assumptions Expected Term 1	5 years
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Values Assumptions Expected Term 1	3 years 4 months 2 days
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions Expected Rates	91.94%	73.37%
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions Expected Rates	78.98%
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions Expected Rates	65.33%
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions Expected Rates	2.46%	2.09%
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions Expected Rates	1.95%
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions Expected Rates	1.49%
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions Expected Rates	0.00%	0.00%

Defined Contribution Plan (Deta

Defined Contribution Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Description of Defined Contribution Pension and Other Postretirement Plans	Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code.
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	50.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	6.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 33	$ 97